Managed Care Guide to Crohn’s Disease

CE

Hit the Ground Running in Crohn’s Disease: A Managed Care Guide to Advanced Biologic Therapies and Early Interventions to Improve Long-term Outcomes

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: April 30, 2025

Expiration: April 29, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

After receiving an anti-TNF biologic for 7 yr, a patient is having diminished response. Switch to a selective IL-23 inhibitor has been prescribed, but the patient wants to know more about these medications. Which best describes results from clinical trials for patients who received a selective IL-23 inhibitor after failure on at least 1 other type of biologic therapy?

2.

Your organization is trying to decide whether incorporating another biologic for CD into its formulary, to provide more patient options, could provide direct economic benefit. Which of the following would provide the most accurate data for the decision?

3.

In patients with moderate to severe CD, starting biologic therapy >2 yr after diagnosis, compared with sooner after diagnosis, is associated with . . .